Cart (0 Items)
Your cart is currently empty.
View ProductsTildrakizumab Biosimilar – Anti-IL23A mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Tildrakizumab Biosimilar - Anti-IL23A mAb - Research Grade |
|---|---|
| Source | CAS 1326244-10-3 |
| Species | Humanized |
| Expression system | Mammalian cells |
| Molecular weight | 144kDa |
| Purity | >85% |
| Buffer | PBS buffer PH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 3-5 weeks if production needed |
| Storage condition | store at -80°C |
| Brand | ProteoGenix |
| Applications | ELISA,WB |
| Aliases /Synonyms | Tildrakizumab,MK-3222, SCH900222,IL23A,anti-IL23A |
| Reference | PX-TA1309 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG1-kappa |
| Clonality | Monoclonal Antibody |
Description of Tildrakizumab Biosimilar - Anti-IL23A mAb - Research Grade
General information on Anti-IL23A[Homo sapiens] (Tildrakizumab) Monoclonal Antibody
Tildrakizumab is a humanized IgG1 kappa antibody that targets interleukin 23 p19 with high affinity. It is investigated for the treatment of chronic plaque psoriasis.
Related products
Antigen
Human IL23A recombinant protein
PX-P5123 110€
SIL
Reviews
Il n’y a pas encore d’avis.